Related Experiment Video
Updated: May 22, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Treatment effects on patient-important outcomes can be small, even with large effects on surrogate markers
Stephen D Walter1, Xin Sun, Diane Heels-Ansdell
1Department of Clinical Epidemiology and Biostatistics, McMaster University, HSC-2C16, Hamilton, Ontario L8N 3Z5, Canada. walter@mcmaster.ca
Objective:
Surrogate markers are often used in clinical trials if too much time or expense is involved to observe the effect of treatment on patient-important outcomes. We wished to estimate the ultimate effects of treatment when randomized trials have addressed only a surrogate marker, and additional, independent studies evaluate the association between the surrogate and the final outcome.
Study Design And Setting:
We show how to calculate the overall effect of treatment on a final outcome, together with its standard error and confidence interval. The methods are illustrated with data on the effect of therapy on hepatitis B seroconversion, a surrogate marker, and its association with patient-important outcomes (cirrhosis and liver cancer).
Results:
We find that the effect of treatment on the final outcome may be small even if there are strong associations between treatment and the surrogate and between the surrogate and the patient-important outcome.
Conclusion:
Apparently, robust treatment effects on surrogates are likely to lead to small and uncertain effects on patient-important outcomes. We should be cautious in advising patients to adopt a therapy when compelling evidence is restricted to its impact on surrogate outcomes, particularly if that therapy may be toxic or otherwise cause harms.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Regression Toward the Mean
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Bioequivalence of Drugs: Drugs with Multiple Indications
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test